CPR Invest - Reactive - A EUR - Acc ISIN : LU1103787690
CPR Invest - Reactive - A EUR - Acc
A(C) - LU1103787690
Asset class: Balanced
YTD
As of 17/11/2026-0.06%
Risk IndicatorThe level of risk of the fund mainly reflects the risk of the market in which the fund is invested and, as the case may be, the leveraging strategy or inverse performance of the index. The capital initially invested does not benefit from any guarantee. The current level of risk does not indicate the future level of risk and may change over time. The lowest risk level is not equal to a risk-free investment.
1234567
Lower Risk
Higher Risk
The risk indicator assumes you keep the product according to the holding period.
NAV
As of 17/11/2026€1,348.14
SFDR ClassificationSustainable Finance Disclosure Regulation
Art. 8
Fund AUM
As of 17/11/2026€58.92M
This international diversified sub-fund aims to outperform its benchmark index over a minimum of 4 years with maximum projected volatility of 15%. The portfolio's equity exposure ranges from 20% to 80% and its interest-rate sensitivity from -2 to +5. The sub-fund is a feeder fund for the French mutual fund CPR Croissance Réactive.
NAVs
NAV from 21/11/2016 to 17/11/2026
Select period
Performance
Change in NAV in base 100
FundCPR Invest - Reactive - A EUR - Acc (24.38% over the period)
Select period
B. Since the beginning of this period, the reference indicator of the Sub-Fund is the capitalized €STR.Performance published and achieved before the date of the change corresponds to a different strategy from the current one.
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.
All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.
Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.
The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).
The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.
Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.
The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).
The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
Change in NAV in base 100Rolling performancesYear-on-year return (365 days)Annual returnsRisk indicatorsPerformances Scenarios
FundCPR Invest - Reactive - A EUR - Acc (24.38% over the period)
Select period
B. Since the beginning of this period, the reference indicator of the Sub-Fund is the capitalized €STR.Performance published and achieved before the date of the change corresponds to a different strategy from the current one.
* Rolling performance : for funds that have been launched since less than 1 year or 3 years or 5 years, the performance showed in the table in the 1 year or 3 years or 5 years column is the performance since inception of the fund.
All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.
Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.
The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).
The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
All performance figures are calculated in your selected currency based NAV to NAV with gross income accumulated.
Past performance does not guarantee future returns. The value of an investment can rise or fall with market fluctuations, and you may lose the amount originally invested. The material is based upon information that we consider reliable as of the date shown, but we do not represent that it is accurate, complete, valid or timely, in particular any data communicated to us by a third party, and it should not be relied on as such for any particular purpose. All material is subject to change.
The fund performance is calculated net of investment management fees including commissions and custody fees. The benchmark performances are calculated with net dividend reinvested when applicable. Both performances for funds and benchmarks are calculated using internal software fed by external sources (predominantly Datastream).
The exchange rates used to convert the benchmark and investment funds are the rates published by WM/Reuters at 16:00 (London time) on the last day of the month.
Portfolio Analysis
Repartition 10/31/2026
Main Lines in Portfolio (Source: Amundi)Geographical breakdown (Source: Amundi)CurrencyPortfolio Breakdown by Maturity (Source: Amundi)
Sector | Weight | |
|---|---|---|
| AM EURO LIQUIDITY S-T RESP - Z (C) | Money Market Investments | 9.75% |
| CPR INVEST - CLIMATE BONDS EURO - Z EUR | Investment Grade EMU | 6.55% |
| AMUNDI EURO LIQUIDITY SELECT - Z (C) | Money Market Investments | 6.18% |
| AM MSCI WRLD SCREENED UCITS ETF (PAR) | Equities World | 5.46% |
| abrdn Em Mkt Lcl Ccy Dbt K Acc EUR | Govies Emerging Global | 5.41% |
| CPR ABSOLUTE RETURN BONDS - Z (C) | Absolute Return Fixed Income | 5.35% |
| Amundi USD Corporate Bond ESG ETF DR C | Investment Grade USA | 5.18% |
| CPR INVEST - CREDIXX GLOB HI YIELD | High Yield World | 4.72% |
| ARI - EUROPEAN CREDIT- I2 - C | Investment Grade EMU | 4.24% |
| BFT CREDIT OPPORT ISR CLIMAT - I2 (C) | Investment Grade Europe | 3.84% |
Management commentary
Effective date: 31/10/2026The month of October was marked by a new surge in energy prices, against a backdrop of persistent geopolitical tensions in the Middle East. Brent crude rose by nearly 14%, while natural gas returned to its highest levels since the end of 2022. This dynamic led to an acceleration in headline inflation in both the eurozone and the United States, without, at this stage, causing a comparable increase in core components. Economic activity remained generally resilient, particularly in the United States, even though the deterioration of the US labor market and the slowdown in European business surveys sent more mixed signals.
In this context, the Fed, the ECB, and the Bank of Japan kept their key interest rates unchanged, while maintaining cautious communication in the face of inflationary risks. Bond markets benefited from this monetary pause and a flight to safe-haven assets, resulting in a significant decline in sovereign yields. Conversely, equity markets were shaken at the end of the month by disappointing earnings reports from several major technology companies, which reignited questions about the profitability of massive investments in artificial intelligence. Technology stocks, semiconductors, and emerging markets thus underperformed, while European equities and sectors less exposed to the AI theme proved more resilient.
In light of this environment, we maintain a slightly cautious bias on equities. The most concentrated exposures to large US technology stocks, the Nasdaq, and semiconductors have been reduced, as well as certain thematic and emerging market positions. These adjustments aim to limit the sensitivity of allocations to segments with the highest valuation levels and earnings expectations. At the same time, we are favoring broader indices to improve diversification and reduce concentration risk.
From a sector perspective, we are strengthening our preference for healthcare and energy. Healthcare offers more defensive characteristics, better earnings visibility, and relatively limited sensitivity to the economic cycle. Energy, for its part, benefits from rising hydrocarbon prices and serves as a partial hedge against persistent geopolitical and inflationary tensions. Exposure to emerging markets remains more measured, given their sensitivity to the technology sector, the ongoing weakness of Chinese domestic demand, and a still restrictive rate environment.
In bond markets, we favor a contained duration, mainly in the five- to seven-year maturities. This positioning allows us to benefit from carry and a potential further easing of yields, while limiting exposure to longer maturities, which are more vulnerable to a renewed rise in inflation expectations. Government bonds also continue to play an important role in diversification and protection in the event of renewed risk aversion in equity markets.
Within credit, the euro investment grade segment remains favored due to the quality of issuers and an always attractive risk-return profile. US high yield also offers an interesting source of carry, but only within a rigorous selection framework, given the level of financing rates and the risks of dispersion among issuers. Finally, emerging market debt in local currencies can provide additional diversification, provided a selective approach is maintained regarding currency, inflation, and monetary policy risks specific to each country.
In this context, the Fed, the ECB, and the Bank of Japan kept their key interest rates unchanged, while maintaining cautious communication in the face of inflationary risks. Bond markets benefited from this monetary pause and a flight to safe-haven assets, resulting in a significant decline in sovereign yields. Conversely, equity markets were shaken at the end of the month by disappointing earnings reports from several major technology companies, which reignited questions about the profitability of massive investments in artificial intelligence. Technology stocks, semiconductors, and emerging markets thus underperformed, while European equities and sectors less exposed to the AI theme proved more resilient.
In light of this environment, we maintain a slightly cautious bias on equities. The most concentrated exposures to large US technology stocks, the Nasdaq, and semiconductors have been reduced, as well as certain thematic and emerging market positions. These adjustments aim to limit the sensitivity of allocations to segments with the highest valuation levels and earnings expectations. At the same time, we are favoring broader indices to improve diversification and reduce concentration risk.
From a sector perspective, we are strengthening our preference for healthcare and energy. Healthcare offers more defensive characteristics, better earnings visibility, and relatively limited sensitivity to the economic cycle. Energy, for its part, benefits from rising hydrocarbon prices and serves as a partial hedge against persistent geopolitical and inflationary tensions. Exposure to emerging markets remains more measured, given their sensitivity to the technology sector, the ongoing weakness of Chinese domestic demand, and a still restrictive rate environment.
In bond markets, we favor a contained duration, mainly in the five- to seven-year maturities. This positioning allows us to benefit from carry and a potential further easing of yields, while limiting exposure to longer maturities, which are more vulnerable to a renewed rise in inflation expectations. Government bonds also continue to play an important role in diversification and protection in the event of renewed risk aversion in equity markets.
Within credit, the euro investment grade segment remains favored due to the quality of issuers and an always attractive risk-return profile. US high yield also offers an interesting source of carry, but only within a rigorous selection framework, given the level of financing rates and the risks of dispersion among issuers. Finally, emerging market debt in local currencies can provide additional diversification, provided a selective approach is maintained regarding currency, inflation, and monetary policy risks specific to each country.
Characteristics
General data
Inception date
29/08/2014First Nav Date
18/04/1997Currency
EURShow more
Valuation
DailyMinimum initial investment
1 10/1000° share(s)/equityMinimum additional investment
1 10/1000° share(s)/equityCosts Composition
| One-off costs upon entry or exit (Investment EUR 10,000) | If you exit after 1 year | ||
| Entry costs | This includes distribution costs of 5.00% of amount invested. This is the most you will be charged. The person selling you the product will inform you of the actual charge. | Up to €500.00 | |
| Exit costs | We do not charge an exit fee for this product, but the person selling you the product may do so. | €0.00 | |
| Ongoing costs taken each year (Investment EUR 10,000) | |||
| Management fees and other administrative or operating costs | 2.30% of the value of your investment per year. This percentage is based on actual costs over the last year. | €218.88 | |
| Transaction costs | We do not charge a transaction fee for this product | €0.00 | |
| Incidental costs taken under specific conditions (Investment EUR 10,000) | |||
| Performance fees | 20.00% annual outperformance of the reference asset 100% ESTR CAPITALISE (OIS). The calculation applies on each Net Asset Value calculation date in accordance with the terms described in the prospectus. Past underperformances over the last 5 years should be clawed back before any new accrual of performance fee.The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years. The performance fee is paid even if the performance of the share over the performance observation period is negative, while remaining higher than the performance of the Reference Asset. | €0.00 | |
Codification
ISIN code
LU1103787690Bloomberg code
CPRRCAC LXReuters code
LP68277370Investment Objective
This international diversified sub-fund aims to outperform its benchmark index over a minimum of 4 years with maximum projected volatility of 15%. The portfolio's equity exposure ranges from 20% to 80% and its interest-rate sensitivity from -2 to +5. The sub-fund is a feeder fund for the French mutual fund CPR Croissance Réactive.
Documents
| Language | Documents | Type | Closing Date |
|---|---|---|---|
CS | PDF | 17/06/2026 | |
PDF | 01/10/2026 | ||
EN | PDF | 31/07/2025 | |
PDF | 31/01/2026 | ||
CS | PDF | 31/10/2026 | |
PDF | 01/04/2026 | ||
EN | PDF | 26/10/2016 |
Sustainability-related disclosures
| Language | Documents | Type | Closing Date |
|---|---|---|---|
EN | PDF | 01/01/2023 | |
PDF | 03/08/2026 | ||
PDF | 01/01/2025 | ||
CS | PDF | 01/01/2025 |
Prices expressed in a currency other than the base currency of the portfolio are available for information purposes only.
Nothing contained in this site constitutes a solicitation or offer by any member of the Amundi to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". Amundi does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.
Nothing contained in this site constitutes a solicitation or offer by any member of the Amundi to provide any investment advice or service or to purchase or sell any financial instruments. The information it contains aims to inform the subscriber by providing information on the UCITS supplemental to that appearing in the Information Memorandum. The material provided on this site is presented as of the date shown and "as is". Amundi does not expressly or impliedly warrant the accuracy of the information provided on this site and expressly disclaims any warranties of fitness of this site for any particular purpose. This material reflects the opinion of the management company at the date of printing. The material is based upon information that we consider reliable, but we do not represent it is accurate, complete, valid or timely and it should not be relied on as such for any particular purpose. Any subscription should be based solely on the Information Memorandum provided to subscribers prior to the subscription and/or available upon request.